Sabine Poiret

TL;DR: Results show that the in vivo protective capacity of the studied lactic acid bacteria (LAB) could be predicted based on the cytokine profile established in vitro, and the PBMC-based assay used may serve as a useful primary indicator to narrow down the number of candidate strains to be tested in murine models for their anti-inflammatory potential.

TL;DR: It is concluded that not all lactobacilli have similar effects on intestinal inflammation and that selected probiotics such as L. salivarius Ls-33 may be considered in the prevention or treatment of intestinal inflammation.

TL;DR: LcrV-secreting L lactis decreased experimentally induced intestinal inflammation in 2 murine models of colitis, highlighting the potential of using pathogen-derived immunomodulating molecules in vivo as novel therapeutics for inflammatory bowel diseases.

TL;DR: In this paper, low calcium response V (LcrV) protein synthesized by gram-negative, pathogenic yersiniae participates in bacterial evasion of the host's innate immune response by stimulating synthesis of the anti-inflammatory interleukin (IL)-10 and preventing the activation of proinflammatory cytokines.

TL;DR: It is shown that the recombinant strain induced specific systemic and mucosal antibody and cellular immune responses after intranasal immunization and protected mice against both oral and systemic Y. pseudotuberculosis infections.